Skip to main content
    A

    Arcutis Biotherapeutics Inc (ARQT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.15
    -1.11 (-3.93%)

    Market Cap: $3.57B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcutis Biotherapeutics Inc (ARQT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Arcutis Biotherapeutics are Arcus Biosciences (RCUS), Tarsus Pharmaceuticals (TARS) and Legend Biotech (LEGN). By market cap, Arcutis Biotherapeutics ranks 5th of the 13 companies on this page; Travere Therapeutics (TVTX) is the largest at $4.86B.

    Peer Comparison

    ARQT's ROIC of 7.8% is above the peer median of -41.8%, and its revenue growth of 45.1% is above the median of 13.3%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Arcutis Biotherapeutics (ARQT)$3.57B129.3x7.0x5.9%7.8%45.1%0.00%
    Arcus Biosciences Inc (RCUS)$2.51BN/A21.5x0.0%-75.9%-65.4%0.00%
    Tarsus Pharmaceuticals Inc (TARS)$3.96BN/A5.4x-102.9%-393.6%63.9%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Travere Therapeutics Inc (TVTX)$4.86BN/A7.2x-18.7%-23.1%36.2%0.00%
    Crispr Therapeutics AG (CRSP)$4.10BN/A155.2x0.0%-20.3%1325.0%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Dyne Therapeutics Inc (DYN)$3.22BN/AN/A0.0%-42.9%0.0%0.00%
    Viking Therapeutics Inc (VKTX)$3.73BN/AN/A0.0%-61.0%0.0%0.00%
    Viridian Therapeutics Inc (VRDN)$3.51BN/A128.5x0.0%-41.8%-63.5%0.00%
    Xencor Inc (XNCR)$2.78BN/A13.5x-58.8%-17.3%454.9%0.00%
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Vericel Corp Ord (VCEL)$2.91B89.8x9.1x10.3%N/A26.5%0.00%
    Peer median$3.31B178.2x13.5x0.0%-41.8%13.3%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Arcutis Biotherapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Arcus Biosciences Inc (RCUS)
    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States.
    RCUS competitors
    Tarsus Pharmaceuticals Inc (TARS)
    Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates...
    TARS competitors
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors
    Travere Therapeutics Inc (TVTX)
    Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification...
    TVTX competitors
    Crispr Therapeutics AG (CRSP)
    CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases.
    CRSP competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Dyne Therapeutics Inc (DYN)
    Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases...
    DYN competitors
    Viking Therapeutics Inc (VKTX)
    Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders.
    VKTX competitors
    Viridian Therapeutics Inc (VRDN)
    Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses.
    VRDN competitors
    Xencor Inc (XNCR)
    Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed...
    XNCR competitors
    MBX Biosciences, Inc. Common Stock (MBX)
    MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment...
    MBX competitors
    Vericel Corp Ord (VCEL)
    Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures...
    VCEL competitors

    Frequently Asked Questions About ARQT

    Who are Arcutis Biotherapeutics' main competitors?

    The companies most similar to Arcutis Biotherapeutics include Arcus Biosciences (RCUS), Tarsus Pharmaceuticals (TARS), Legend Biotech (LEGN), Travere Therapeutics (TVTX) and Crispr Therapeutics AG (CRSP), listed from the closest match.

    Who is Arcutis Biotherapeutics' biggest competitor?

    Travere Therapeutics (TVTX) is the largest of the similar companies at $4.86B; Arcus Biosciences (RCUS) is the closest match by business profile, size, sector and industry.

    How does ARQT stock compare with its competitors?

    ARQT's P/E is 129.3x against a peer median of 178.2x; its P/S is 7.0x against a peer median of 13.5x; its net margin is 5.9% against a peer median of 0.0%.

    Which of Arcutis Biotherapeutics' competitors pays a higher dividend?

    Arcutis Biotherapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Arcutis Biotherapeutics bigger than its competitors?

    No. Arcutis Biotherapeutics is 5th by market cap among the 13 companies on this page; the largest is Travere Therapeutics (TVTX) at $4.86B.